Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab mafodotin in Chinese participants with RRMM
NCT04177823Phase 1Completed
- Sponsor
- GSK
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of belantamab mafodotin in multiple myeloma (MM) (2 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs), Number of Participants With Serious Adverse Events (SAEs) and 1 more. Started Dec 2019; status: completed.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04177823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177823.